2020
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers In Psychiatry 2020, 11: 595584. PMID: 33424664, PMCID: PMC7786299, DOI: 10.3389/fpsyt.2020.595584.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersGABAergic medicationsReuptake inhibitorsRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialPanic disorderStress disorderSpecific phobiaBeta-adrenergic medicationsPlacebo-controlled trialCurrent pharmacological treatmentsNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCause of disabilityPrevalent psychiatric disordersNovel pharmacotherapeutic agentsBeta-adrenergic agentsSocial anxiety disorderMixed antidepressantsGlutamate modulatorsGlutamatergic agentsObsessive-compulsive disorder
2006
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Annals Of Global Health 2006, 73: 941-9. PMID: 17195879.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-traumatic stress disorderCognitive behavioral therapyFear conditioningUnconditioned stimulusAnxiety disordersPartial NMDA agonistFear inhibitionFear extinctionTraumatic memoriesFear circuitryFear responsesPavlovian conditioningBehavioral therapyStress disorderSpecific phobiaNew learningAmygdala pathwayD-cycloserineAnti-anxiety treatmentPanic disorderPreliminary evidenceStimuliMemoryN-methyl-D-aspartate antagonistsNeurobiology